Search
A Memorial Sloan Kettering Cancer Center study shows that the use of MRI before or immediately after surgery in women with DCIS was not associated with reduced local recurrence or contralateral breast cancer rates.
A new type of CAR T cell therapy for multiple myeloma could shorten the time to treatment.
Learn how intermittent fasting is being explored by researchers for possible use in cancer treatment and prevention, including breast cancer.
The Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) at Memorial Sloan Kettering Cancer Center (MSK) today announced The Pat and Ian Cook Doctoral Program in Cancer Engineering, made possible by a generous gift of $15 million from Pat and Ian Cook.
The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology.
MSK researchers used the genome-editing tool CRISPR to create more potent chimeric antigen receptor (CAR) T cells that don't tire as easily when attacking cancer cells. The unexpected findings were published in the journal Nature on February 22 and underscore the potential of genome editing to advance immunotherapy for cancer.
On November 10, 2025, hundreds gathered in the Mortimer B. Zuckerman Research Center for the “MSK Innovation with Lasting Impact Summit: Entrepreneurship & Innovation at MSK,” at an event that brought together laboratory and clinical researchers, digital health innovators, healthcare executives, and investors.
Learn about MSK’s active surveillance program for papillary thyroid cancer, which allows many people to avoid unnecessary surgery and the risks that come with it.
Obtenga información sobre el programa de observación activa de MSK para el cáncer de tiroides papilar, que permite a muchas personas evitar cirugías innecesarias y los riesgos que estas tienen.
Though questions remain about how best to use genetic testing for cancer, the trend is toward more inclusive criteria.